Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies

In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of epidemiology 2016-08, Vol.184 (4), p.325-335
Hauptverfasser: Karim, Mohammad Ehsanul, Gustafson, Paul, Petkau, John, Tremlett, Helen
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 335
container_issue 4
container_start_page 325
container_title American journal of epidemiology
container_volume 184
creator Karim, Mohammad Ehsanul
Gustafson, Paul
Petkau, John
Tremlett, Helen
description In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time-dependent analyses, such as fitting a time-dependent Cox model. The prescription time-distribution matching (PTDM) method has been proposed as a simpler approach for controlling immortal time bias. Using simulation studies and theoretical quantification of bias, we compared the performance of the PTDM approach with that of the time-dependent Cox model in the presence of immortal time. Both assessments revealed that the PTDM approach did not adequately address immortal time bias. Based on our simulation results, another recently proposed observational data analysis technique, the sequential Cox approach, was found to be more useful than the PTDM approach (Cox: bias = -0.002, mean squared error = 0.025; PTDM: bias = -1.411, mean squared error = 2.011). We applied these approaches to investigate the association of β-interferon treatment with delaying disability progression in a multiple sclerosis cohort in British Columbia, Canada (Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study, 1995-2008).
doi_str_mv 10.1093/aje/kwv445
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4983651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1812222719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-447435a8f28815e4e4c3a7a8aa2b1b0a0117c877f2ebf6ff316334f18d4f76143</originalsourceid><addsrcrecordid>eNpVkU1v1DAQhi0EotvChR-AfERIof6K7VyQyrZApUocKOJozXrHuy5JHGxnEf--QVsqmMsc5tE7M3oIecXZO846eQ53eP7j10Gp9glZcWV0o0Wrn5IVY0w0ndDihJyWcscY513LnpMTYVTbdlquSFinYYIcSxppCvRrhRpLjR56ejFNOYHfY6EhZXqJ0MdxR7_HuqfXw5ByXaDbOCD9EKHQONLLPO_oVQjoazzgiKUsgfM2YnlBngXoC7586Gfk28er2_Xn5ubLp-v1xU3jpbG1Ucoo2YINwlreokLlJRiwAGLDNwyWB4y3xgSBm6BDkFxLqQK3WxWM5kqekffH3GneDLj1ONYMvZtyHCD_dgmi-38yxr3bpYNTnZW65UvAm4eAnH7OWKobYvHY9zBimovjloulDO8W9O0R9TmVkjE8ruHM_RHjFjHuKGaBX_972CP614S8B3Tii-8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1812222719</pqid></control><display><type>article</type><title>Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Karim, Mohammad Ehsanul ; Gustafson, Paul ; Petkau, John ; Tremlett, Helen</creator><creatorcontrib>Karim, Mohammad Ehsanul ; Gustafson, Paul ; Petkau, John ; Tremlett, Helen ; Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group</creatorcontrib><description>In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time-dependent analyses, such as fitting a time-dependent Cox model. The prescription time-distribution matching (PTDM) method has been proposed as a simpler approach for controlling immortal time bias. Using simulation studies and theoretical quantification of bias, we compared the performance of the PTDM approach with that of the time-dependent Cox model in the presence of immortal time. Both assessments revealed that the PTDM approach did not adequately address immortal time bias. Based on our simulation results, another recently proposed observational data analysis technique, the sequential Cox approach, was found to be more useful than the PTDM approach (Cox: bias = -0.002, mean squared error = 0.025; PTDM: bias = -1.411, mean squared error = 2.011). We applied these approaches to investigate the association of β-interferon treatment with delaying disability progression in a multiple sclerosis cohort in British Columbia, Canada (Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study, 1995-2008).</description><identifier>ISSN: 0002-9262</identifier><identifier>EISSN: 1476-6256</identifier><identifier>DOI: 10.1093/aje/kwv445</identifier><identifier>PMID: 27455963</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Bias ; Confounding Factors (Epidemiology) ; Drug Evaluation - statistics &amp; numerical data ; Humans ; Interferon-beta - therapeutic use ; Models, Statistical ; Multiple Sclerosis - drug therapy ; Observational Studies as Topic ; Practice of Epidemiology ; Proportional Hazards Models ; Time Factors ; Treatment Outcome</subject><ispartof>American journal of epidemiology, 2016-08, Vol.184 (4), p.325-335</ispartof><rights>The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>The Author 2016. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-447435a8f28815e4e4c3a7a8aa2b1b0a0117c877f2ebf6ff316334f18d4f76143</citedby><cites>FETCH-LOGICAL-c378t-447435a8f28815e4e4c3a7a8aa2b1b0a0117c877f2ebf6ff316334f18d4f76143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27455963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karim, Mohammad Ehsanul</creatorcontrib><creatorcontrib>Gustafson, Paul</creatorcontrib><creatorcontrib>Petkau, John</creatorcontrib><creatorcontrib>Tremlett, Helen</creatorcontrib><creatorcontrib>Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group</creatorcontrib><title>Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies</title><title>American journal of epidemiology</title><addtitle>Am J Epidemiol</addtitle><description>In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time-dependent analyses, such as fitting a time-dependent Cox model. The prescription time-distribution matching (PTDM) method has been proposed as a simpler approach for controlling immortal time bias. Using simulation studies and theoretical quantification of bias, we compared the performance of the PTDM approach with that of the time-dependent Cox model in the presence of immortal time. Both assessments revealed that the PTDM approach did not adequately address immortal time bias. Based on our simulation results, another recently proposed observational data analysis technique, the sequential Cox approach, was found to be more useful than the PTDM approach (Cox: bias = -0.002, mean squared error = 0.025; PTDM: bias = -1.411, mean squared error = 2.011). We applied these approaches to investigate the association of β-interferon treatment with delaying disability progression in a multiple sclerosis cohort in British Columbia, Canada (Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study, 1995-2008).</description><subject>Bias</subject><subject>Confounding Factors (Epidemiology)</subject><subject>Drug Evaluation - statistics &amp; numerical data</subject><subject>Humans</subject><subject>Interferon-beta - therapeutic use</subject><subject>Models, Statistical</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Observational Studies as Topic</subject><subject>Practice of Epidemiology</subject><subject>Proportional Hazards Models</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0002-9262</issn><issn>1476-6256</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1v1DAQhi0EotvChR-AfERIof6K7VyQyrZApUocKOJozXrHuy5JHGxnEf--QVsqmMsc5tE7M3oIecXZO846eQ53eP7j10Gp9glZcWV0o0Wrn5IVY0w0ndDihJyWcscY513LnpMTYVTbdlquSFinYYIcSxppCvRrhRpLjR56ejFNOYHfY6EhZXqJ0MdxR7_HuqfXw5ByXaDbOCD9EKHQONLLPO_oVQjoazzgiKUsgfM2YnlBngXoC7586Gfk28er2_Xn5ubLp-v1xU3jpbG1Ucoo2YINwlreokLlJRiwAGLDNwyWB4y3xgSBm6BDkFxLqQK3WxWM5kqekffH3GneDLj1ONYMvZtyHCD_dgmi-38yxr3bpYNTnZW65UvAm4eAnH7OWKobYvHY9zBimovjloulDO8W9O0R9TmVkjE8ruHM_RHjFjHuKGaBX_972CP614S8B3Tii-8</recordid><startdate>20160815</startdate><enddate>20160815</enddate><creator>Karim, Mohammad Ehsanul</creator><creator>Gustafson, Paul</creator><creator>Petkau, John</creator><creator>Tremlett, Helen</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160815</creationdate><title>Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies</title><author>Karim, Mohammad Ehsanul ; Gustafson, Paul ; Petkau, John ; Tremlett, Helen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-447435a8f28815e4e4c3a7a8aa2b1b0a0117c877f2ebf6ff316334f18d4f76143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Bias</topic><topic>Confounding Factors (Epidemiology)</topic><topic>Drug Evaluation - statistics &amp; numerical data</topic><topic>Humans</topic><topic>Interferon-beta - therapeutic use</topic><topic>Models, Statistical</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Observational Studies as Topic</topic><topic>Practice of Epidemiology</topic><topic>Proportional Hazards Models</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karim, Mohammad Ehsanul</creatorcontrib><creatorcontrib>Gustafson, Paul</creatorcontrib><creatorcontrib>Petkau, John</creatorcontrib><creatorcontrib>Tremlett, Helen</creatorcontrib><creatorcontrib>Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karim, Mohammad Ehsanul</au><au>Gustafson, Paul</au><au>Petkau, John</au><au>Tremlett, Helen</au><aucorp>Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies</atitle><jtitle>American journal of epidemiology</jtitle><addtitle>Am J Epidemiol</addtitle><date>2016-08-15</date><risdate>2016</risdate><volume>184</volume><issue>4</issue><spage>325</spage><epage>335</epage><pages>325-335</pages><issn>0002-9262</issn><eissn>1476-6256</eissn><abstract>In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of the period between cohort entry and first treatment exposure during follow-up may result in immortal time bias. This bias can be eliminated by acknowledging a change in treatment exposure status with time-dependent analyses, such as fitting a time-dependent Cox model. The prescription time-distribution matching (PTDM) method has been proposed as a simpler approach for controlling immortal time bias. Using simulation studies and theoretical quantification of bias, we compared the performance of the PTDM approach with that of the time-dependent Cox model in the presence of immortal time. Both assessments revealed that the PTDM approach did not adequately address immortal time bias. Based on our simulation results, another recently proposed observational data analysis technique, the sequential Cox approach, was found to be more useful than the PTDM approach (Cox: bias = -0.002, mean squared error = 0.025; PTDM: bias = -1.411, mean squared error = 2.011). We applied these approaches to investigate the association of β-interferon treatment with delaying disability progression in a multiple sclerosis cohort in British Columbia, Canada (Long-Term Benefits and Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study, 1995-2008).</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>27455963</pmid><doi>10.1093/aje/kwv445</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9262
ispartof American journal of epidemiology, 2016-08, Vol.184 (4), p.325-335
issn 0002-9262
1476-6256
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4983651
source MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Bias
Confounding Factors (Epidemiology)
Drug Evaluation - statistics & numerical data
Humans
Interferon-beta - therapeutic use
Models, Statistical
Multiple Sclerosis - drug therapy
Observational Studies as Topic
Practice of Epidemiology
Proportional Hazards Models
Time Factors
Treatment Outcome
title Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A28%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Statistical%20Approaches%20for%20Dealing%20With%20Immortal%20Time%20Bias%20in%20Drug%20Effectiveness%20Studies&rft.jtitle=American%20journal%20of%20epidemiology&rft.au=Karim,%20Mohammad%20Ehsanul&rft.aucorp=Long-Term%20Benefits%20and%20Adverse%20Effects%20of%20Beta-Interferon%20for%20Multiple%20Sclerosis%20(BeAMS)%20Study%20Group&rft.date=2016-08-15&rft.volume=184&rft.issue=4&rft.spage=325&rft.epage=335&rft.pages=325-335&rft.issn=0002-9262&rft.eissn=1476-6256&rft_id=info:doi/10.1093/aje/kwv445&rft_dat=%3Cproquest_pubme%3E1812222719%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1812222719&rft_id=info:pmid/27455963&rfr_iscdi=true